11 March 2025 – Sydney, Australia | ReNerve Limited (ASX:RNV) ("ReNerve" or "the Company") is pleased to announce key milestones in its Asian market expansion, including marketing approval for the NervAlign® Nerve Cuff™ in Thailand, as well as its first hospital stocking order in Hong Kong. These developments strengthen ReNerve’s commercial presence outside the initial market it has entered in the United States, and supports its global growth strategy in solutions for peripheral nerve injury, repair, and regeneration.
Highlights
-
NervAlign® Nerve Cuff approved for sale in Thailand, paving the way for commercial rollout in the nation of 70+ million people.
-
First stocking order has also been received from a hospital in Hong Kong, marking the product’s first clinical use in the region.
-
Strategic Expansion in Asia – Thailand’s large population and position as a medical tourism hub provide significant market opportunities.
Commenting on the approval in Thailand, ReNerve CEO, Dr Julian Chick, stated: “The approval in Thailand is another step forward in the development of ReNerve’s operations in Asia and our plans to expand beyond the US. The initial order in Hong Kong is a significant milestone in that market and will serve as a reference for ongoing sales in the region."
About the NervAlign® Nerve Cuff™
The NervAlign® Nerve Cuff™ is a bioabsorbable medical device designed to:
-
Protect repaired nerves while promoting regeneration.
-
Dissolve naturally within six months, leaving only regenerated nerve tissue.
-
Be used in plastic, trauma, and reconstructive surgeries, including breast augmentation, gender reassignment, and extremity revision surgeries.
Thailand’s thriving medical tourism industry, particularly in plastic and reconstructive surgery, presents strong demand potential for the NervAlign® Nerve Cuff.
About us:
About ReNerve Limited:
ReNerve Limited (ASX:RNV) is a medical device company specialising in advanced nerve repair and regeneration solutions. The Company is focused on commercialising cutting-edge medical devices and tissue-engineering products that seek to address significant unmet needs for patients with peripheral nerve damage – a critical gap in healthcare. ReNerve aims to improve patient outcomes through scientifically backed products that have been developed to enhance the human body's natural healing process, while commercialising cutting-edge, scalable products for the healthcare market. ReNerve wishes to acknowledge AusIndustry’s Accelerating Commercialisation program for its support through many of the activities required to commercialise the NervAlign® Nerve Cuff.
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]